



caliRx

**Insulin Patient
Advisory Council
Quarterly Meeting**



April 28, 2026

Virtual Meeting Etiquette



1

Mute your microphone when you are not speaking to avoid background noise



2

Use of your camera is encouraged



3

Raise your virtual hand or use the chat feature for questions/comments



Meeting Operating Principles



- Communicate clearly and concisely
- Ensure all participants who wish to speak, have the chance to do so
- Respectfully listen to the perspective of others
- Ask questions if clarification is needed
- Avoid jargon whenever possible
- Keep comments relevant to the issue being discussed

Agenda



- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 1. Welcome & Introductions New Council Member Introductions Biosimilar Insulin Initiative Overview Review Insulin PAC Role & Responsibilities | 2:30 PM |
| 2. 2025 Biosimilar Insulin Initiative Accomplishments | 3:15 PM |
| 3. CalRx [®] Insulin Glargine Pen Distribution & Communications Updates | 3:35 PM |
| 4. Next Steps & Adjournment | 3:45 PM |



New Council Member Introductions

Members Appointed for 2026-27 Term Year



- **Albert Bach, Pharm.D.**
Providence Medical Foundation
- **Allison Hardt**
Community Development Director
T1International
- **Ani Shenian, Pharm.D.**
Ambulatory Care Clinical Pharmacist
- **Christopher Noble**
Organizing Director, Health Access CA
- **Craig Stubing**
CEO, Beta Cell Foundation
- **Daniela Grijalva Moreno**
Graduate MPH Candidate, Brown University
- **Diana Wyenn**
Director and Creative Producer
- **Joe L. Garbanzos**
State President (volunteer), AARP-CA
- **Kathryn Topalis, M.D.**
Diabetes Lead, Ambulatory Care Network
Los Angeles Department of Health Services
- **Luz Gallegos**
Executive Director, TODEC Legal Center
- **Michelle Chu, Pharm.D.**
Primary Care Clinic
Los Angeles General Medical Center
- **Samantha Lappin**
T1International Chapter Member
Talent Acquisition Recruiter, DAP Health

Biosimilar Insulin Initiative: Overview

CalRx[®]: State-powered market intervention for better drug affordability and access



- The California Affordable Drug Manufacturing Act of 2020 (Senate Bill 852, Statutes of 2020) empowered California to enter into partnerships resulting in the production, procurement, or distribution of generic drugs at a low price for consumers.
- Target areas are drugs where the U.S. health care system has failed to lower drug costs, even when a generic or biosimilar medication is available.
- All CalRx[®] pricing is based on development, production, and distribution costs without rebates or other discounts (other than federally mandated ones).
- The CalRx[®] program is housed within the California Department of Health Care Access & Information (HCAI).

Our Vision: An equitable, transparently priced pharmaceutical market where all Californians can afford and access the medications they need for healthy lives.

Our Purpose & Intervention Models



- CalRx's purpose is to **improve equitable access and affordability of medications** in California by developing strategic partnerships and innovative solutions in the pharmaceutical market.
- To date, there are 3 major initiatives under our program:

CalRx Models for Intervention

1. Invest in development (insulin model)
2. Stockpiling (misoprostol model)
3. Leverage state volume for white labels¹ (naloxone model)



CalRx® Biosimilar Insulin Initiative



Reproductive Health Stockpile



CalRx® Naloxone Access Initiative

Civica and CalRx: Partnering for Affordable Insulin

- Civica, Inc. (Civica Rx) – a mission-driven, nonprofit generic company created to ensure reliable and affordable access to medicines
- Civica is developing and will manufacture and distribute insulins at significantly lower prices than insulins currently on the market
- 3 interchangeable insulins:
 1. Glargine (Lantus®)
 2. Aspart (Novolog®)
 3. Lispro (Humalog®)
- One-price model – no hidden rebates or price concessions





Civica Petersburg

- 140,000 square feet
- 350 employees at full staffing
- 90 million vials/year
- 50 million syringes/year
- 120 million prefilled pens/year

Council's Role & Responsibilities

Council's Purpose



- Serve the CalRx[®] Biosimilar Insulin Initiative in an advisory capacity
- Provide input and guidance to advance awareness, education, and advocacy for CalRx[®] low-cost biosimilar insulin products for all patients throughout California
- Provide insights and expertise on alternative distribution models, barriers in the insulin market, and ensuring equitable access to insulin for diverse communities

The Council will...

- Share insights and feedback as consumers of insulin products
- Advocate for inclusion of CalRx[®] insulin in traditional outlets
- Offer guidance on how to reach patients through non-traditional outlets
- Increase awareness of CalRx[®] insulin products
- Provide input on patient education materials

The Council will not...

- Have decision-making authority
- Have access to non-public and confidential information
- Receive compensation or a stipend for meeting participation

Council Member's Role



- Support the success of the CalRx[®] Biosimilar Insulin Initiative through regular participation in Council meetings
- Help define the Council's annual goals and provide input on various activities, such as:
 - Evaluating options to distribute CalRx[®] insulin products broadly
 - Disseminating accurate information about CalRx[®] insulin quality, safety, and cost-effectiveness
 - Implementing social media campaigns
- Refer to the commitments listed on your **Appointment Acceptance Form**

Council Meeting Logistics



- The Council will meet quarterly via video conference
- Meetings are scheduled in advance for the term year
- Agendas will be sent out no later than one week prior to the meeting
- Minutes will be sent out with the agenda for the upcoming meeting
- Meetings are not subject to the Bagley-Keene Open Meeting Act and are not open to the public
- Meetings are not confidential and all records including agendas, minutes, and materials are public record
- Public-facing events may be planned

Communication with the Public & Media



- Council members may speak to the media in a personal capacity about their views
- Direct media inquiries regarding official CalRx[®] information to:
info@calrx.ca.gov

Council Resources



[CalRx Statute](#)

[CalRx Website](#)
(Meeting Materials Archive)

Council Coordinator
Sarah Turner
info@calrx.ca.gov

[Council Charter](#)



Questions



Biosimilar Insulin Initiative: 2025 Accomplishments

Extensive distribution for CalRx[®] insulins is imperative




The success of this program hinges on reaching diverse communities



This includes vulnerable populations grappling with affordability challenges in accessing insulin

Certain traditional supply chain models for drug distribution might present formidable barriers



Breaking into these established systems and ensuring equitable access for all can be a daunting task, but one that is crucial for the program's overall effectiveness

We recognize the significance of collaboration



By identifying the areas where HCAI's expertise can be most impactful, we can work in tandem with Civica to bridge gaps and overcome distribution challenges

A collaborative distribution approach will complement Civica's commercialization efforts



Market Analysis

HCAI-led

Gather diabetes, income, and census data in HCAI's centralized data warehouse to identify target geographical regions. Overlay with pharmacy, retail, and federally qualified health center location data.



Education & Advocacy

HCAI-led

Utilize educational programs, marketing campaigns, and social media platforms to raise awareness of CalRx insulins, particularly in target segments



Traditional Supply Channels

Civica-led

Contract with wholesalers, pharmacy benefit managers, health plans, and pharmacies to include CalRx insulins



Formulary Inclusion

Civica-led

Engage in conversations with health plans, pharmacy benefit managers, and retail pharmacies to encourage the inclusion of CalRx products in their formularies & implement legislation



Explore Non-Traditional Supply Channels

Co-led


As feasible, collaborate with non-traditional distribution partners such as safety-net providers, community clinics, and federally qualified health centers to facilitate distribution



Monitoring & Support

Co-led

Establish a customer support system to address inquiries on "where to find CalRx products". Implement a monitoring system to measure the effectiveness of the distribution strategy.



Equitable insulin distribution will develop in phases




 Civica-led
 Co-led



Use the traditional supply model to establish broad access for both the insured and uninsured population



Add additional retail pharmacy options in low-income communities with high diabetes prevalence



As feasible, develop alternative distribution methods to close access gaps for consumers that lack a fixed address or live in pharmacy deserts

CalRx[®] Biosimilar Insulin Initiative 2025 Accomplishments



Refreshed market analysis with HCAI's Healthcare Payments Data (HPD); evaluated diabetes prevalence & insurance coverage rates at zip code level



Kicked off the CalRx Insulin Patient Advisory Council; created social media posts and educational materials for patients & prescribers



Announced 2026 launch of CalRx Insulin Glargine Pen through traditional wholesale model & broad pharmacy network



Secured formulary agreements with Anthem Blue Cross of CA, Blue Shield of CA, and Federal Employees Plan

Universities Allied for Essential Medicines (UAEM) 2026 North American Conference



**Public Pharma Panel (from left to right):
Allison, Kate, Sarah, Chris**
[Watch Recording](#)

2026 Council Meeting Roadmap*

*This is subject to change.



April

- Welcome new Council members & orientation
- 2025 Biosimilar Insulin Initiative accomplishments
- CalRx® Insulin Glargine Pen distribution & communications updates

July

- Insulin distance dashboard presentation by HCAI
- Data discussion questions

October

- TBA



Thank you.

**Next Council Meeting:
Tuesday, July 28, 2026
2:30 – 4:30 p.m. (PST)**